For how we live.
In a 98-patient French trial, six-monthly rituximab did not extend remission beyond daily azathioprine in this rare eosinophilic vasculitis — and recipients had more severe infections.
Rhapsido becomes the first drug labelled for the itchy welts raised by scratching or pressure. In the RemIND trial, 29.3% on the pill cleared the provocation test at week 12 versus 14.0% on placebo.
In a 134-patient phase 3 crossover trial, deucrictibant — the first oral bradykinin B2 receptor blocker — brought symptom relief in a median 1.28 hours, against more than 12 hours on placebo.
Thirteen years on, the independent DiAPREV-IT trial still shows no overall effect from GAD-alum. A 27-child genetic subgroup saw onset delayed — but the other subgroup got worse.
A randomised Asian trial in 130 patients found no efficacy gap between the two drug regimens for active lupus nephritis, but serious infections and all three deaths fell in the mycophenolate group.
In the DIABIL-2 trial, low-dose interleukin-2 hit its immune target in people newly diagnosed with type 1 diabetes, yet failed to preserve insulin-producing cells at one year.
AMPLIFIED enriched for early rheumatoid arthritis patients thought to respond best to abatacept, then compared it head-to-head with adalimumab. At week 24 the two drugs were indistinguishable.
In the phase 3 INDIGO trial, weekly obexelimab roughly halved the risk of a flare in this rare fibroinflammatory disease and spared patients steroids — a positive result in a condition with no approved drug.
REPLENISH randomised 381 patients with relapsed polymyalgia rheumatica. Sustained remission at 52 weeks reached about 41% on secukinumab versus 20.4% on placebo. Novartis funded the trial.
Yes, within limits. Short sleep is linked to more colds and weaker vaccine responses, but the strongest effects turn up when sleep is measured objectively, not from what people report.
You cannot turn a healthy immune system up like a dial, and nothing on the supplement shelf has been shown to. What the trials do show is narrower: fix a sleep deficit and you catch fewer colds.
In PHOENYCS GO, dapirolizumab pegol lifted the share of lupus patients reaching a composite response at 48 weeks to 50% from 35% on placebo — a real but modest 14.6-point gain.
Chronic hives are mast-cell driven and usually have no external trigger. Antihistamines clear some cases; at 12 weeks omalizumab cut a weekly itch score by 9.8 points at 300 mg, against 5.1 on placebo.
Open-label follow-up of the phase 3 LUNA3 trial shows rilzabrutinib's platelet responses were durable and sometimes appeared in people who had not responded at first — but a minority reached the mark.
Colds come from viruses, not cold air. But chilling the body and breathing cold air can blunt the nose's antiviral defences enough to tip a lurking infection into symptoms.
In the 2,137-participant PrEggNut trial, mothers who ate a diet rich in eggs and peanuts through pregnancy and breastfeeding had infants with the same allergy rate as the comparison group.
In a 142-patient phase 3 trial, 37% reached complete remission on the antibody obinutuzumab versus 6% on tacrolimus at two years. A key kidney-function endpoint was not met, tempering the result.
A single-centre randomised trial found that three cycles of intravenous immunoglobulin on top of high-dose steroids improved muscle disease faster and further — in just 44 patients, at one Dutch hospital.
The ORBEX trial gave OM-85 or placebo to 822 young children at high risk of asthma. Wheezing lower-respiratory illnesses were, if anything, slightly more common on the drug.
Satralizumab reduced eye-bulging and inflammation in thyroid eye disease across the twin SatraGO phase 3 trials, but the primary proptosis endpoint reached statistical significance in only one of them.
Most infections end when the immune system clears them. A few have evolved ways to hide, integrate or persist — which is why they can last a lifetime, and why 'cure' means something different for each.
It hangs in the air for up to two hours and infects the great majority of susceptible people it reaches. Less well known: it can erase part of the immune memory a person had already built to other diseases.
A real condition with a formal case definition, a measurable population-level burden, and — so far — no treatment proven to reverse it. What the studies do and do not establish.
Every vaccine does the same job — teach the immune system to recognise a pathogen before it arrives. What differs is how they show it the target: live, inactivated, protein, viral vector, or mRNA.
Rezpegaldesleukin works by expanding the immune system's regulatory T cells rather than blocking an inflammatory signal — a new mechanism for atopic dermatitis, tested so far only in a phase 2b study.
Farm-raised children really are protected from asthma, and the mechanism has been traced to microbial exposure and innate immunity. What has not been shown is that household hygiene caused the allergy epidemic.
Dazukibart eased skin and muscle disease within weeks and held up for nearly two years — but the trials were tiny, manufacturer-run, and the makers say a phase 3 is needed to confirm it.
Blood samples from a West African vaccine trial show both licensed Ebola vaccines generate antibodies that bind Bundibugyo virus — the species with no vaccine of its own, now causing DRC's largest outbreak on record.
A randomised-withdrawal trial showed the antibody-lowering drug kept CIDP patients in remission. A 2026 extension reports lasting benefit, but with no placebo group to measure it against.
In the COSPIRIT-JIA trial, most children with two stubborn forms of juvenile idiopathic arthritis responded to ixekizumab by week 16 — but the main result had no control group.
In the ALLEGORY trial, 76.7% of patients with active SLE reached the SRI-4 response at 52 weeks on the B-cell–depleting antibody versus 53.5% on placebo, extending a drug already cleared for lupus nephritis.
A study in patients with VITT maps the trigger to a specific epitope on an adenoviral core protein, and to a single amino acid change that redirects the antibody onto a human platelet protein.
Three laureates, three papers, and a 30-year gap between the first observation and the therapies it enabled. The prize rewards work that was against the consensus when it was published.